NCIC CLINICAL TRIALS GROUP

GENITOURINARY

DISEASE SITE COMMITTEE MEETING

AGENDA

Hilton Montréal Bonaventure, Montréal, Québec
Saturday, April 29, 2006 - 9:00 a.m. - 3:30 p.m.
Room: Hampstead/Cote St. Luc
Chair: Martin Gleave

9:00 a.m.  WELCOME  M. Gleave
Approval of Fall Meeting Minutes
Chairman’s Report

9:10 a.m.  NCIC CTG PHASE III TRIALS: OPEN  B. Donnelly
PR.8  L. Wood/A. Aprikian
BL.8 / EORTC 30994  L. Klotz
BL.10

9:40 a.m.  NCIC CTG PHASE III TRIALS: CLOSED  J. Crook/L. Klotz
PR.7 / PR.7 bone sub study
PR.3  P. Warde
PRP.1  N. Fleshner
PRP.1B – open to accrued patients  N. Fleshner
BL.7 (EORTC 30987)  E. Winquist/M. Moore

9:50 a.m.  NCIC CTG TRIALS APPROVED/PENDING ACTIVATION  L. Klotz
PR.11
BL.11  L. Lacombe

10:05 a.m.  CTSU TRIALS ENDORSED BY NCIC CTG  M. Gleave
*CALGB 90203 NHT Taxotere in high risk localized CaP
CALGB 90202 HT with or without zoledronic acid in hormone naïve met CaP  F. Saad
* trial in development

10:20 a.m.  BREAK

10:40 a.m.  NCIC CTG IND TRIALS  K. Chi
IND.154: Phase I OGX-011 + Taxotere (closed)
IND.161: Triapine Phase II (closed)  J. Knox
IND.165: Randomized Phase II (OGX-011 +/- docetaxel HRPC)  K. Chi
IND.167: (BAY 43-9006 prostate) (closed)

continued . . .
11:00 p.m. **OPEN CUOG TRIALS**

CUOG-R-05 Role of Delayed Treatment for Early Stage RCCa  
M. Jewett

CUOG-P-05 RCT Risedronate vs Placebo for the Prevention of Androgen Deprivation Bone Loss in Non-Metastatic Prostate Cancer  
F. Saad

CUOG B-05 BMS/CUOG second line bladder trial with vinflunine  
E. Winquist

CUOG/CURC CHICS Trial  
L. Klotz

CUOG P-06a Phase III Trial of docetaxel +/- high dose of Calcitriol  
K. Chi

12:00 p.m. **LUNCH**

1:00 p.m. **PENDING CUOG TRIALS**

CUOG P-06b Phase II Study of Patupilone (Epo906a) as a 2nd Line Therapy in HRPC  
K. Chi

CUOG P-06c Phase II Study of OGX-011 + docetaxel as a 2nd Line Chemotherapy in HRPC  
F. Saad/E. Winquist

Taxotere Adjuvant Trial (Aventis)  
D. Drachenberg/S. North

Sutent as salvage therapy in NSGCT  
C. Kollmannsberger

1:40 p.m. **CLOSED CUOG TRIALS**

CUOG P-01b (NHT Taxotere)  
M. Gleave

Taxotere as 2nd Line in HRPC  
F. Saad

Iressa® for Rising PSA post RP  
L. Klotz

2:00 p.m. **TRIALS UNDER DEVELOPMENT**

**NCIC CTG**

NHT + Taxotere prior to XRT  
M. McKenzie

Stampede (MRC)  
F. Saad

RADICAL: Randomized Phase III trial of adjuvant versus selective salvage treatment after radical prostatectomy for high-risk localized prostate cancer (MRC)  
C. Catton/C. Morash

MRC/NRCI/NCIC CTG collaborative efforts  
N. James/C. Parker/M. Sydes

ECOG RCCa adjuvant trial  
M. Jewett/L. Wood

**CUOG**

IAS plus dutasteride in PSA failures  
L. Klotz/S.L. Goldenberg

ELAAT – early vs late Androgen Ablation Therapy  
A. Loblaw

Hypo fractionation RT in localized prostate cancer  
C. Catton

3:15 p.m. **OPEN DISCUSSION – NEW BUSINESS, STRATEGIC PLANNING**

3:30 p.m. **GU EXECUTIVE (CLOSED)**